Gaining a Foothold: Amyloid Immunotherapy in Clinical Practice
Lecanemab will soon have maintenance dosing and subcutaneous formulations available; FDA advisory committee will consider donanemab June 10.
6415 RESULTS
Sort By:
Lecanemab will soon have maintenance dosing and subcutaneous formulations available; FDA advisory committee will consider donanemab June 10.
An adeno-associated virus that binds the transferrin receptor delivered β-glucocerebrosidase throughout the mouse brain.
APOE4 carriers who also have a glycine-to-glutamic-acid substitution in the extracellular matrix protein were much less likely to develop Alzheimer’s disease.
Blood and other in vitro assays will need to meet the same standards as medical devices, including demonstrating diagnostic accuracy.
By age 65, nearly all people who carry two copies of APOE4 harbor neuropathological or biomarker evidence of AD pathology.
In mice and cultured human neurons, PLCγ2 knockdown thinned out synapses and suppressed neuron firing. Rare loss-of-function PLCγ2 variants hike AD risk 10-fold.
People who had a damaged locus coeruleus accumulated tangles in their medial temporal lobes over the next three years, and their cognition declined.
Known for shuttling APP, the endosomal receptor latches on to tau. Knocking it down in glia reduced tau seeding. The N1358S risk variant ramped it up.
First papers from MoTrPAC initiative report myriad responses to endurance training in multiple organs in rats, including the brain and heart.
In the DIAN familial AD prevention trial, plaque-busting antibody gantenerumab, but not monomer-targeting solanezumab, nudged fluid markers toward normal.
Tauopathy cranks up lipid synthesis in neurons, which slip the fats to microglia. Blocking AMP kinase greases this process.
Amyloid precursor protein CTFs accumulate in lysosomes adjacent to endoplasmic reticulum. This disrupts calcium flow between the organelles.
Scientists find the senescent subtype has a distinct protein signature, but little change in gene expression, causing it to be overlooked in transcriptomic studies.
Lysosomes deliver a plethora of mRNA transcripts, including those encoding ribosomal subunits and mitochondrial proteins, to axonal terminals for translation.
In a small Phase 2 trial, the GLP-1 analogue lixisenatide stabilized motor abilities over one year in people with early PD.
No filters selected